Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery

DISEASE CHARACTERISTICS: * Histologically confirmed primary cancer of the colon or rectum * Isolated hepatic metastases * Not amenable to curative resection or requirement for complex and or larger (i.e., \> 4 liver segments) liver resection * Measurable disease (RECIST criteria) * Original tumor must be (or have been) removed PATIENT CHARACTERISTICS: Inclusion criteria: * WHO performance status 0-1 * Life expectancy \> 3 months * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9 g/dL * Creatinine ≤ 1.5 times normal * Bilirubin ≤ 1.5 times upper limit of normal * Transaminases ≤ 5 times normal * Not pregnant or nursing * Fertile patients must use effective contraception Exclusion criteria: * Contraindication or allergy grade 3-4 to any components of the study drugs * Peripheral neuropathy * Intestinal occlusion or subocclusion or prior inflammatory intestinal disease * Severe cardiac disease including any of the following: * Symptomatic coronary disease * Myocardial infarction in the past 6 months * New York Heart Association grade II-IV cardiac insufficiency * Severe arrhythmia (even if treated) * Active or uncontrolled infection * Other concurrent serious disorder * Severe uncontrolled medical condition * Other malignancy within the past 5 years or concurrently except basal cell skin cancer or carcinoma in situ of the cervix * Study impossible due to psychological, geographical, or social reasons * Prisoners or patients under guardianship PRIOR CONCURRENT THERAPY: Exclusion criteria: * Prior chemotherapy except adjuvant chemotherapy comprising fluorouracil, leucovorin calcium, capecitabine, oxaliplatin, irinotecan hydrochloride, and/or bevacizumab (completed \> 6 months ago if oxaliplatin- or irinotecan-based) * Prior epidermal growth factor (EGF), monoclonal antibody inhibiting transduction of EGF receptor (EGFR), or any other treatment targeting the EGFR * Other concurrent anticancer immunotherapy, chemotherapy, or hormone therapy * Participation in another study in the past 30 days